TY - JOUR
T1 - Best practices recommendations in the application of immunohistochemistry in the kidney tumors
T2 - Report from the International Society of Urologic Pathology Consensus Conference
AU - Reuter, Victor E.
AU - Argani, Pedram
AU - Zhou, Ming
AU - Delahunt, Brett
PY - 2014/8
Y1 - 2014/8
N2 - Primary renal neoplasms comprise multiple distinct entities, some of which are well understood and others that are not. It is not uncommon for some of these entities to have overlapping morphologic features. Their clinical behavior is varied, ranging from highly malignant to benign, and metastatic renal cell carcinoma oftentimes enters into the differential diagnosis of tumors of unknown primary. In this age of personalized medicine, identifying biomarkers that can better predict clinical outcome and response to therapy is a pressing need. In 2013 the International Society of Urological Pathology held a meeting in which best practices recommendations on the use of immunohistochemical markers in urologic malignancies were discussed. In this review we make recommendations regarding immunohistochemical markers that are best suited to aid in establishing a diagnosis of renal primary, panels of antibodies that are most useful in classifying renal tumors, and the current status of prognostic and predictive biomarkers. Although no prognostic or predictive marker and set of markers have yet to be validated, ongoing research suggests that this fact is likely to change in the near future.
AB - Primary renal neoplasms comprise multiple distinct entities, some of which are well understood and others that are not. It is not uncommon for some of these entities to have overlapping morphologic features. Their clinical behavior is varied, ranging from highly malignant to benign, and metastatic renal cell carcinoma oftentimes enters into the differential diagnosis of tumors of unknown primary. In this age of personalized medicine, identifying biomarkers that can better predict clinical outcome and response to therapy is a pressing need. In 2013 the International Society of Urological Pathology held a meeting in which best practices recommendations on the use of immunohistochemical markers in urologic malignancies were discussed. In this review we make recommendations regarding immunohistochemical markers that are best suited to aid in establishing a diagnosis of renal primary, panels of antibodies that are most useful in classifying renal tumors, and the current status of prognostic and predictive biomarkers. Although no prognostic or predictive marker and set of markers have yet to be validated, ongoing research suggests that this fact is likely to change in the near future.
KW - ISUP recommendations
KW - best practices
KW - immunohistochemistry
KW - kidney tumors
KW - renal cell carcinoma
KW - renal neoplasm
UR - http://www.scopus.com/inward/record.url?scp=84904464120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904464120&partnerID=8YFLogxK
U2 - 10.1097/PAS.0000000000000258
DO - 10.1097/PAS.0000000000000258
M3 - Article
C2 - 25025368
AN - SCOPUS:84904464120
SN - 0147-5185
VL - 38
SP - e35-e49
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
IS - 8
ER -